SHR‐1703, a novel long‐acting anti‐interleukin‐5 monoclonal antibody, in asthma patients: A randomized, double‐blind, placebo‐controlled phase 1 study

Documenti analoghi

• Safety, tolerability, pharmacokinetics and pharmacodynamics of HSK31858, a novel oral dipeptidyl peptidase‐1 inhibitor, in healthy volunteers: An integrated phase 1, randomized, double‐blind, placebo‐controlled, single‐ and multiple‐ascending dose study
  di: Yuhao Wang, et al.
  Pubblicazione: (2025)
• Effects of intraoperative low‐dose esketamine on postoperative pain after vestibular schwannoma resection: A prospective randomized, double‐blind, placebo‐controlled study
  di: Kaizheng Chen, et al.
  Pubblicazione: (2024)
• Mild psoriasis as a suitable model for proof‐of‐mechanism in a phase 1B setting: Results from a double‐blind placebo‐controlled trial with guselkumab
  di: Jannik Rousel, et al.
  Pubblicazione: (2025)
• Effects of a pro‐resolving drug in COVID‐19: preclinical studies to a randomized, placebo‐controlled, phase Ib/IIa trial in hospitalized patients
  di: Pedro R. J. Almeida, et al.
  Pubblicazione: (2024)
• Antiviral activity, safety and PK/PD of ACC017 in antiretroviral naïve HIV‐infected adults: A randomized, double‐blind, placebo/dose‐parallel‐controlled short‐term monotherapy study
  di: N. Han, et al.
  Pubblicazione: (2025)